• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种改进观察性索赔研究中癌症治疗和结局的健康状况测量的新方法。

A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes.

出版信息

J Geriatr Oncol. 2013 Apr;4(2):157-65. doi: 10.1016/j.jgo.2012.12.005.

DOI:10.1016/j.jgo.2012.12.005
PMID:23795223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3685201/
Abstract

OBJECTIVES

To develop and provide initial validation for amultivariate, claims-based prediction model for disability status (DS), a proxymeasure of performance status (PS), among older adults. The model was designed to augment information on health status at the point of cancer diagnosis in studies using insurance claims to examine cancer treatment and outcomes.

MATERIALS AND METHODS

We used data from the 2001–2005 Medicare Current Beneficiary Survey (MCBS), with observations randomly split into estimation and validation subsamples. We developed an algorithm linking self-reported functional status measures to a DS scale, a proxy for the Eastern Cooperative Oncology Group (ECOG) PS scale. The DS measure was dichotomized to focus on good [ECOG 0–2] versus poor [ECOG 3–4] PS. We identified potential claims-based predictors, and estimated multivariate logistic regression models, with poor DS as the dependent measure, using a stepwise approach to select the optimal model. Construct validity was tested by determining whether the predicted DS measure generated by the model was a significant predictor of survival within a validation sample from the MCBS.

RESULTS AND CONCLUSION

One-tenth of the beneficiaries met the definition for poor DS. The base model yielded high sensitivity (0.79) and specificity (0.92); positive predictive value=48.3% and negative predictive value=97.8%, c-statistic=0.92 and good model calibration. Adjusted poor claims-based DS was associated with an increased hazard of death (HR=3.53, 95% CI 3.18, 3.92). The ability to assess DS should improve covariate control and reduce indication bias in observational studies of cancer treatment and outcomes based on insurance claims.

摘要

目的

开发并提供一种基于多元索赔数据的、针对老年人残疾状态(DS)的预测模型,并初步验证其有效性,DS 是一种绩效状态(PS)的替代指标。该模型旨在增加癌症诊断时健康状况的信息,以便在使用保险索赔数据研究癌症治疗和结果的研究中使用。

材料与方法

我们使用了来自 2001-2005 年医疗保险当前受益人调查(MCBS)的数据,观察结果随机分为估计和验证子样本。我们开发了一种算法,将自我报告的功能状态测量值与 DS 量表(ECOG PS 量表的替代指标)联系起来。DS 量表被二分为关注良好[ECOG 0-2]与不良[ECOG 3-4]PS。我们确定了潜在的基于索赔的预测因素,并使用逐步方法选择最优模型,对不良 DS 作为因变量的多变量逻辑回归模型进行了估计。使用 MCBS 中的验证样本,通过确定模型预测的 DS 测量值是否是生存的显著预测因素来测试结构有效性。

结果与结论

十分之一的受益符合不良 DS 的定义。基础模型具有较高的灵敏度(0.79)和特异性(0.92);阳性预测值=48.3%,阴性预测值=97.8%,c 统计量=0.92,模型校准良好。调整后的不良索赔 DS 与死亡风险增加相关(HR=3.53,95%CI 3.18,3.92)。在基于保险索赔的癌症治疗和结果的观察性研究中,评估 DS 的能力应该改善协变量控制并减少指示偏差。

相似文献

1
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes.一种改进观察性索赔研究中癌症治疗和结局的健康状况测量的新方法。
J Geriatr Oncol. 2013 Apr;4(2):157-65. doi: 10.1016/j.jgo.2012.12.005.
2
Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.验证残疾状况,一种基于索赔的癌症治疗和结局研究的功能状态衡量方法。
Med Care. 2014 Jun;52(6):500-10. doi: 10.1097/MLR.0000000000000122.
3
Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data.利用行政索赔数据评估晚期非小细胞肺癌的功能状态及化疗的生存获益。
Lung Cancer. 2015 Jan;87(1):59-64. doi: 10.1016/j.lungcan.2014.10.011. Epub 2014 Nov 13.
4
Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups.基于索赔数据的方法在十个肿瘤组中对ECOG体能状态进行代理评估的开发与验证。
J Comp Eff Res. 2018 Mar;7(3):193-208. doi: 10.2217/cer-2017-0040. Epub 2018 Mar 13.
5
Predicting Disability among Community-Dwelling Medicare Beneficiaries Using Claims-Based Indicators.使用基于理赔数据的指标预测社区医保受益人的残疾情况
Health Serv Res. 2016 Feb;51(1):262-81. doi: 10.1111/1475-6773.12316. Epub 2015 May 25.
6
A cardiovascular disease risk prediction algorithm for use with the Medicare current beneficiary survey.一种用于医疗保险当前受益人大调查的心血管疾病风险预测算法。
Health Serv Res. 2020 Aug;55(4):568-577. doi: 10.1111/1475-6773.13290. Epub 2020 Apr 14.
7
Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States.美国新诊断多发性骨髓瘤老年患者基于索赔的残疾状况代理表现状态定义下的死亡率。
J Geriatr Oncol. 2019 May;10(3):490-496. doi: 10.1016/j.jgo.2019.01.007. Epub 2019 Jan 30.
8
Controlling for Frailty in Pharmacoepidemiologic Studies of Older Adults: Validation of an Existing Medicare Claims-based Algorithm.控制老年人药物流行病学研究中的脆弱性:基于医疗保险索赔的现有算法的验证。
Epidemiology. 2018 Jul;29(4):556-561. doi: 10.1097/EDE.0000000000000833.
9
Zostavax vaccine effectiveness among US elderly using real-world evidence: Addressing unmeasured confounders by using multiple imputation after linking beneficiary surveys with Medicare claims.使用真实世界证据评估美国老年人中Zostavax疫苗的有效性:通过将受益人的调查与医疗保险理赔数据相链接后采用多重填补法来处理未测量的混杂因素。
Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):993-1001. doi: 10.1002/pds.4801. Epub 2019 Jun 5.
10
Identifying neuropsychiatric disorders in the Medicare Current Beneficiary Survey: the benefits of combining health survey and claims data.在医疗保险当前受益人调查中识别神经精神疾病:整合健康调查和理赔数据的益处。
BMC Health Serv Res. 2016 Oct 1;16(1):537. doi: 10.1186/s12913-016-1774-y.

引用本文的文献

1
Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data.无病生存期作为食管癌真实世界中总生存期的替代指标:基于监测、流行病学和最终结果(SEER)-医疗保险数据的分析
ESMO Open. 2024 Nov;9(11):103934. doi: 10.1016/j.esmoop.2024.103934. Epub 2024 Nov 6.
2
The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC.免疫检查点抑制剂在老年非小细胞肺癌患者中的毒性与疗效的相关性。
Immunotherapy. 2024;16(16-17):1057-1068. doi: 10.1080/1750743X.2024.2394382. Epub 2024 Sep 13.
3
Unleashing frailty from laboratory into real world: A critical step toward frailty-guided clinical care of older adults.从实验室到现实世界释放脆弱性:迈向老年衰弱患者临床护理的关键一步。
J Am Geriatr Soc. 2024 Nov;72(11):3299-3314. doi: 10.1111/jgs.19151. Epub 2024 Aug 21.
4
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases.免疫检查点抑制剂作为老年非小细胞肺癌合并同步脑转移患者的后续治疗手段
Transl Lung Cancer Res. 2024 Jul 30;13(7):1620-1634. doi: 10.21037/tlcr-24-205. Epub 2024 Jul 25.
5
Assessing the Benefits and Harms of Pharmacotherapy in Older Adults with Frailty: Insights from Pharmacoepidemiologic Studies of Routine Health Care Data.评估衰弱老年人药物治疗的获益和危害:来自常规医疗保健数据的药物流行病学研究的启示。
Drugs Aging. 2024 Jul;41(7):583-600. doi: 10.1007/s40266-024-01121-0. Epub 2024 Jul 2.
6
Predictors of high-intensity care at the end of life among older adults with solid tumors: A population-based study.预测老年人实体瘤患者生命终末期高强度医疗的因素:一项基于人群的研究。
J Geriatr Oncol. 2024 Jun;15(5):101774. doi: 10.1016/j.jgo.2024.101774. Epub 2024 Apr 26.
7
Association of cancer diagnosis with disability status among older survivors of colorectal cancer: a population-based retrospective cohort study.老年结直肠癌幸存者中癌症诊断与残疾状况的关联:一项基于人群的回顾性队列研究。
Front Oncol. 2024 Mar 15;14:1283252. doi: 10.3389/fonc.2024.1283252. eCollection 2024.
8
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.他汀类药物的使用与老年原发性血小板增多症和特发性骨髓纤维化患者的生存及血栓发生率。
Cancer Med. 2023 Sep;12(18):18889-18900. doi: 10.1002/cam4.6528. Epub 2023 Sep 13.
9
Translation of a Claims-Based Frailty Index From the International Classification of Diseases, Ninth Revision, Clinical Modification to the Tenth Revision.基于索赔的衰弱指数从国际疾病分类,第九修订版,临床修正到第十版的翻译。
Am J Epidemiol. 2023 Nov 10;192(12):2085-2093. doi: 10.1093/aje/kwad151.
10
Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: A SEER dataset analysis.新诊断的晚期膀胱癌老年患者的治疗模式:一项监测、流行病学和最终结果(SEER)数据集分析
Aging Cancer. 2022 Jun;3(2):105-115. doi: 10.1002/aac2.12048. Epub 2022 Mar 27.

本文引用的文献

1
Use of geriatric assessment for older adults in the oncology setting: a systematic review.老年综合评估在肿瘤治疗中的应用:系统评价。
J Natl Cancer Inst. 2012 Aug 8;104(15):1133-63. doi: 10.1093/jnci/djs285. Epub 2012 Jul 31.
2
Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysis.化疗治疗和生存的老年妇女与雌激素受体阴性转移性乳腺癌:基于人群的分析。
J Am Geriatr Soc. 2011 Apr;59(4):637-46. doi: 10.1111/j.1532-5415.2011.03351.x. Epub 2011 Mar 31.
3
Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.基于人群的研究估计,对于局部晚期非小细胞肺癌的老年患者,联合治疗模式具有生存获益。
J Thorac Oncol. 2011 May;6(5):934-41. doi: 10.1097/JTO.0b013e31820eed00.
4
Using claims-based measures to predict performance status score in patients with lung cancer.利用基于索赔的指标预测肺癌患者的表现状态评分。
Cancer. 2011 Mar 1;117(5):1038-48. doi: 10.1002/cncr.25677. Epub 2010 Oct 18.
5
The critical role of observational evidence in comparative effectiveness research.观察性证据在比较有效性研究中的关键作用。
Health Aff (Millwood). 2010 Oct;29(10):1826-33. doi: 10.1377/hlthaff.2010.0630.
6
Why observational studies should be among the tools used in comparative effectiveness research.为什么观察性研究应该成为比较有效性研究中使用的工具之一。
Health Aff (Millwood). 2010 Oct;29(10):1818-25. doi: 10.1377/hlthaff.2010.0666.
7
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.老年晚期非小细胞肺癌患者的化疗与生存获益。
J Clin Oncol. 2010 May 1;28(13):2191-7. doi: 10.1200/JCO.2009.25.4052. Epub 2010 Mar 29.
8
Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation.老年III期结肠癌患者辅助治疗差异的趋势:肿瘤内科医生评估的作用。
Med Care. 2009 Dec;47(12):1229-36. doi: 10.1097/MLR.0b013e3181b58a85.
9
Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.年龄对老年Ⅲ期结肠癌患者辅助化疗生存获益的影响。
J Am Geriatr Soc. 2009 Aug;57(8):1403-10. doi: 10.1111/j.1532-5415.2009.02355.x. Epub 2009 Jun 25.
10
Limits of observational data in determining outcomes from cancer therapy.观察性数据在确定癌症治疗结果方面的局限性。
Cancer. 2008 Jun;112(11):2456-66. doi: 10.1002/cncr.23452.